- 提示:详情请下载说明书。
- 产品描述: Olodanrigan (EMA401, PD-126055, (S) PD-126055) 是一种高度选择性的、具有口服活性的外周限制性 angiotensin II type 2 receptor (AT2R) 拮抗剂。Olodanrigan 的镇痛作用可能涉及抑制增强 AngII/AT2R 诱导的 p38 和 p42/p44 MAPK 激活,从而抑制 DRG 神经元过度兴奋和 DRG 神经元的萌芽
- 靶点: AT2R;RAAS
- 体外研究:
EMA401 may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways
- 体内研究:
EMA401, a selective small molecule antagonist of the AT2R, results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI).
- 细胞实验: Cell lines: rat DRG neurons Concentrations: 10, 100 nM Incubation Time: 30 min Method: 48 h after plating, duplicate dishes were treated with AngII (10 nM), AngII + EMA401 (10 and 100 nM respectively), 100 nM EMA401, NGF (100 ng/ml) or vehicle treated (control 0), for 30 min at 37 ℃, then fixed with 4% PFA for 30 min for immunostaining.
- 动物实验: Animal Models: Adult male Sprague-Dawley (SD) rats with a unilateral chronic constriction injury (CCI) of the sciatic nerve Dosages: 1 mg/kg (i.v.); 10 mg/kg (p.o.) Administration: i.v.; p.o.
- 参考文献:
1. Anand U, et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38. 2. Smith MT, et al.Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 2013 May;14(5):692-705.
- 溶解性: DMSO: ≥ 34 mg/mL
- 保存条件: -20℃
- 配置溶液浓度参考:
1mg 5mg 10mg 1 mM 1.97 ml 9.851 ml 19.701 ml 5 mM 0.394 ml 1.97 ml 3.94 ml 10 mM 0.197 ml 0.985 ml 1.97 ml 50 mM 0.039 ml 0.197 ml 0.394 ml
- 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)